Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 28, 2024Hepatoma ResearchOpen Access

Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSamantha M. RuffTPTimothy M. Pawlik

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ruff et al. (2024) studied this question.

synapsesocial.com/papers/68e6d2ecb6db643587650e23https://doi.org/10.20517/2394-5079.2023.144
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma2026
  2. 2Contemporary Use of Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma2025
  3. 3Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma2025 · 17 citations
  4. 4Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis2024 · 6 citations
  5. 5Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma2024 · 36 citations